Literature DB >> 16275245

Pilot study investigating the age-related decline in ovarian function of regularly menstruating normal women.

Carmen L Pastor1, Vien H Vanderhoof, Lony C-L Lim, Karim A Calis, Ahalya Premkumar, Nadia T Guerrero, Lawrence M Nelson.   

Abstract

OBJECTIVE: To use a pilot study to investigate markers of the age-related decline in ovarian function of regularly menstruating normal women.
DESIGN: Prospective.
SETTING: Tertiary research center. PATIENT(S): Healthy volunteers (n = 42) aged 18 to 50 years who had regular ovulatory menstrual cycles and a prior pregnancy. INTERVENTION(S): A single 300-IU dose of human recombinant FSH on day 3 of the menstrual cycle. MAIN OUTCOME MEASURE(S): Antral follicle count by transvaginal ultrasound and basal and FSH-stimulated serum markers. RESULT(S): Age correlated most strongly with FSH-stimulated inhibin B (r = -0.660), followed by antral follicle count (r = -0.578), basal FSH (r = 0.509), basal Müllerian inhibiting substance (MIS; r = -0.468), and basal inhibin B (r = -0.358). Total antral follicle count correlated most strongly with basal MIS level (r = 0.642). CONCLUSION(S): Of the parameters tested, FSH-stimulated serum inhibin B level had the strongest correlation with age. Basal serum MIS level had the strongest correlation with total antral follicle count. We confirm a previous report that in normal women, the antral follicle count as determined by transvaginal ultrasound examination correlates better with age than do basal FSH and basal inhibin B levels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16275245     DOI: 10.1016/j.fertnstert.2005.05.024

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  5 in total

1.  A prospective evaluation of antral follicle function in women with 46,XX spontaneous primary ovarian insufficiency.

Authors:  Ziad R Hubayter; Vaishali Popat; Vien H Vanderhoof; Obioma Ndubizu; Diane Johnson; Edie Mao; Karim A Calis; James F Troendle; Lawrence M Nelson
Journal:  Fertil Steril       Date:  2009-11-25       Impact factor: 7.329

2.  Assay reproducibility and within-person variation of Müllerian inhibiting substance.

Authors:  Joanne F Dorgan; Cynthia S Spittle; Brian L Egleston; Christiana M Shaw; Lisa L Kahle; Louise A Brinton
Journal:  Fertil Steril       Date:  2009-05-05       Impact factor: 7.329

3.  A validated model of serum anti-müllerian hormone from conception to menopause.

Authors:  Thomas W Kelsey; Phoebe Wright; Scott M Nelson; Richard A Anderson; W Hamish B Wallace
Journal:  PLoS One       Date:  2011-07-15       Impact factor: 3.240

4.  Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk.

Authors:  Joanne F Dorgan; Frank Z Stanczyk; Brian L Egleston; Lisa L Kahle; Christiana M Shaw; Cynthia S Spittle; Andrew K Godwin; Louise A Brinton
Journal:  J Natl Cancer Inst       Date:  2009-10-09       Impact factor: 13.506

5.  Predictors of ovarian reserve in young women with breast cancer.

Authors:  K Lutchman Singh; S Muttukrishna; R C Stein; H H McGarrigle; A Patel; B Parikh; N P Groome; M C Davies; R Chatterjee
Journal:  Br J Cancer       Date:  2007-05-29       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.